Report Reviews Progress at California’s Stem Cell Agency
An external advisory panel recently released a report reviewing progress at the California Institute for Regenerative Medicine, which allocates funds for embryonic stem cell research. The report recommended that CIRM align closer with the biotechnology industry and suspend nonproductive programs. The advisory panel also called for CIRM to scale up its public education efforts.
- "With a Review Pending, the State's Stem Cell Agency Looks for New Leadership, New Therapies and More Money" (Jensen, Sacramento Bee, 11/28).
- "State's Stem Cell Agency Seeks More Time, Money" (Dolan, Los Angeles Times, 11/22).